诚意药业涨2.06%，成交额3814.40万元，主力资金净流入64.81万元

Core Viewpoint - Chengyi Pharmaceutical's stock price has shown significant volatility, with a year-to-date increase of 78.88% but a recent decline in the last five and twenty trading days [2] Group 1: Stock Performance - As of September 24, Chengyi Pharmaceutical's stock price rose by 2.06% to 13.38 CNY per share, with a market capitalization of 4.379 billion CNY [1] - The stock has experienced a decline of 2.97% over the last five trading days and 5.77% over the last twenty trading days, while it increased by 28.04% over the last sixty days [2] - The company has appeared on the trading leaderboard four times this year, with the most recent instance on August 6, where it recorded a net buy of 138 million CNY [2] Group 2: Financial Performance - For the first half of 2025, Chengyi Pharmaceutical reported a revenue of 417 million CNY, representing a year-on-year growth of 17.11%, and a net profit attributable to shareholders of 112 million CNY, up 47.03% year-on-year [2] - The company has distributed a total of 474 million CNY in dividends since its A-share listing, with 203 million CNY distributed over the past three years [3] Group 3: Business Overview - Chengyi Pharmaceutical, established on June 22, 2001, and listed on March 15, 2017, is primarily engaged in the research, production, and sales of chemical pharmaceutical raw materials and formulations [2] - The revenue composition of the company includes 80.99% from formulations, 17.46% from raw materials, 0.63% from traditional Chinese medicine, and minor contributions from intermediates and food [2] - The company operates within the pharmaceutical and biotechnology sector, specifically in chemical pharmaceuticals and formulations, and is involved in various concept sectors including hepatitis treatment and pharmaceutical e-commerce [2]